Engineered immune cells take on sarcoma in early trial
NCT ID NCT06474676
First seen Jun 27, 2026 · Last updated Aug 13, 2026 · Updated 2 times
Summary
This early-phase trial tests a new treatment called attIL12-TIL for people with advanced or metastatic soft tissue and bone sarcoma. The therapy uses a patient's own tumor-fighting immune cells, modified to better target and attack cancer. The study first finds a safe dose, then checks if it can help control liposarcoma growth. About 40 participants aged 12 and older will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BONE SARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Tumor-Injected drug combo outlast standard care in advanced sarcoma?
- Smartwatch exercise plan aims to rebuild fitness in young cancer survivors
- Can an immune-boosting drug make chemotherapy more effective against sarcoma?
- Can tailored exercise help young sarcoma survivors recover strength?
- Blood test may spot hidden sarcoma signals
- Experimental t cell therapy targets sarcoma in small early trial